302356-06-5

Upstream product

• 139403-50-2 (4R,5R,6R)-5,6-Dimethyl-4-(phenylselanylmethyl)tetrahydro-2H-pyran-2-one 
• 302356-05-4 N-{(4S,4aS,6R,8S,8aR)-6-[(R)-3-(tert-Butyl-dimethyl-silanyloxy)-2-methoxy-propyl]-8-methoxy-7,7-dimethyl-hexahydro-pyrano[3,2-d][1,3]dioxin-4-yl}-2-((4S,5R,6R)-5,6-dimethyl-4-phenylselanylmethyl-5,6-dihydro-4H-pyran-2-yl)-2-oxo-acetamide 
• 1666-13-3 diphenyl diselenide 
• 98-88-4 benzoyl chloride 
• 210691-71-7 (3R,4R,5R)-5-(4-Chlorobenzoyloxy)-4-methyl-3-(triphenylmethyoxymethyl)hexanoic acid 
• 210691-73-9 (3S,4R,5R)-5-(4-Chlorobenzoyloxy)-4-methyl-3-(phenylselanylmethyl)hexanoic acid 
• 210691-72-8 (R)-4-[(1R,2R)-2-(4-Chlorobenzoyloxy)-1-methylpropyl]dihydrofuran-2(2H)-one 

Relevant academic research and scientific papers

Synthetic studies on the pederin family of antitumour agents. Syntheses of mycalamide B, theopederin D and pederin

The synthesis of mycalamide B, theopederin D and pederin, which are antitumour agents was discussed. All three compounds were prepared from 6-lithio-2,3-dimethyl-4-phenylselenomethyl-3,4-dihydro-2H-pyran and 2-(3-chloropropyl)-3,3-dimethyl-3,4-dihydro-2H-pyran-4-one. Ground state conformational models were proposed to explain the stereoselectivity of the reactions. The absolute and relative stereochemistry of the compounds has been established by X-ray crystallography and NMR studies.